Canaccord Genuity Reiterates a 'Buy' on Inhibitex (INHX); INX-189/Ribavirin Synergy Supports Nuc Potency

November 30, 2011 8:50 AM EST Send to a Friend
Get Alerts INHX Hot Sheet
Price: $26.00 --0%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 36 | Down: 17 | New: 30
Trade INHX Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Inhibitex (NASDAQ: INHX) price target raised from $15 to $22.00.

Canaccord analyst says, "Increasing our likelihood of 189 approvals in GT2/3 and GT1 HCV treatment subgroups to 40% and 30% from 30% and 20%, respectively, and sticking to an estimated 2015 market launch, we arrive at our new target of $22. For now we see peak 189 sales of $3.7B in 2021 and 40% market share in what could be a $10-15B market for HCV nuc prodrugs. Gilead's (Nasdaq: GILD) intended $11B Pharmasset (Nasdaq: VRUS) acquisition supports this view."

For an analyst ratings summary and ratings history on Inhibitex click here. For more ratings news on Inhibitex click here.

Shares of Inhibitex closed at $13.70 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Add Your Comment